Medtronic, Inc.

$MDT - NYSE - Healthcare Equipment/Supplies
ON 2



Press Release $MDT Medtronic, Inc.

0 COMMENTs 25 Nov
Up 0 0 Down
Endurant II AAA Stent Graft from Medtronic Delivers Durable, Consistent and Proven Outcomes in Real-World Setting

   Presented at VEITH, Three-Year Clinical Data from Global ENGAGE Registry
         Supports Innovative Device's Market-Leading Position Worldwide

MINNEAPOLIS -- Nov. 25, 2013 -- Chosen for nearly one out of every two
endovascular abdominal aortic aneurysm (AAA) repairs worldwide, the Endurant II
AAA stent graft system from Medtronic, Inc. (NYSE: MDT) continues to demonstrate
long-term durability and consistent outcomes at three years in a real-world

The latest data on the market-leading stent graft were presented on Friday at
the VEITHsymposium(TM) in New York City.

The global ENGAGE registry demonstrates Medtronic's unmatched commitment to
clinical research on endovascular aortic repair (EVAR). Its investigators have
enrolled more than 1,200 patients at 79 sites across six continents since the
Endurant system received the CE (Conformité Européenne) mark in June 2008. With
five-year follow-up planned for all patients, the ENGAGE registry represents the
most robust post-market registry ever initiated for a newer generation stent

Results for the 500 registry patients evaluated out to three years show that
graft-related complications were very low, with a 0 percent (n=490)* migration
rate and a Type I/III endoleak rate of 1.5 percent (n=333)*. Additionally, they
show 90.7 percent (n=388)* freedom from secondary endovascular procedures and
98.4 percent (n=417)* freedom from aneurysm-related mortality. Positive results
were also presented for the full 1,263 patient cohort evaluated at two years of

A rigorous monitoring protocol has resulted in follow-up compliance of more than
90 percent in the ENGAGE registry, which is unprecedented for any registry and
improves the reliability of the data.

"The size and scope of the ENGAGE registry distinguish Medtronic among stent
graft makers as a committed partner in building the clinical evidence portfolio
for EVAR worldwide," said ENGAGE investigator Dittmar Böckler, MD, PhD, from the
University Hospital of Heidelberg in Germany, who presented the data. "It is
especially compelling to see that at three years the Endurant system has
maintained durable, long-term outcomes in treating abdominal aortic aneurysms in
a real-world cohort that represents the types of challenging anatomies
physicians encounter in daily clinical practice."

Overall, durable results were sustained across a range of patient anatomies,
including patients with more hostile aortic necks, which have historically been
associated with limited eligibility for endovascular repair and higher rates of
adverse events. The Endurant system is approved for use in patients with neck
lengths of 10mm or greater.

* The n-value in parentheses represents the number of patients at risk for the
event at three years.

                        Global ENGAGE Registry:
Three-Year Outcomes with Endurant AAA Stent Graft

                       Notable Clinical Endpoints

| Whole Body Migration                    |   0%    |
|                                         | (n=490) |
| Type I/III Endoleak                     |  1.5%   |
|                                         | (n=333) |
| Freedom from Secondary Procedure        |  90.7%  |
|                                         | (n=388) |
| Freedom from Aneurysm-Related Mortality |  98.4%  |
|                                         | (n=417) |

Additional analysis of the patient cohort revealed that 18 percent of patients
enrolled had anatomical characteristics that did not fall within the current
instructions for use (IFU), further suggesting that the findings are relevant
and applicable to current clinical practice. In addition, 16 percent of patients
had symptomatic abdominal aortic aneurysms and 10.5 percent were female,
representing the single largest cohort of females in any EVAR trial (n=133).

The Endurant II AAA stent graft system sets the standard for EVAR, with proven
performance in more than 100,000 patients worldwide. With a comprehensive
clinical program that includes nearly 2,000 patients, Medtronic is continuing to
grow the body of clinical evidence for the Endurant II system in both controlled
settings and real-world practice.

In collaboration with leading clinicians, researchers and scientists, Medtronic
offers the broadest range of innovative medical technology for the
interventional and surgical treatment of cardiovascular disease and cardiac
arrhythmias. The company strives to offer products and services that deliver
clinical and economic value to healthcare consumers and providers worldwide.

Medtronic, Inc. (, headquartered in Minneapolis, is the global
leader in medical technology -- alleviating pain, restoring health and extending
life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as
those described in Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from anticipated

                                    - end -

Joseph McGrath
Public Relations

Jeff Warren
Investor Relations

This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
    other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

Source: Medtronic, Inc. via GlobeNewswire

SHARE THIS: Twitter StockTwits LinkedIn Google Plus SHORT URL: